Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.

Publication Type:

Journal Article

Authors:

Birnbaum, Jeanette K; Feng, Ziding; Gulati, Roman; Fan, Jing; Lotan, Yair; Wei, John T; Etzioni, Ruth

Source:

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Volume 24, Issue 4, p.677-82 (2015)

Abstract:

New biomarkers for early detection of cancer must pass through several phases of development. Early phases provide information on diagnostic properties but not on population benefits and harms. Prostate cancer antigen 3 (PCA3) is a promising prostate cancer biomarker still in early development. We use simulation modeling to project the impact of adding PCA3 to prostate-specific antigen (PSA) screening on prostate cancer detection and mortality in the United States.